Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Jianying Yao"'
Autor:
Jiao Liu, Min Shao, Qianghong Xu, Fen Liu, Xiaojun Pan, Jianfeng Wu, Lihong Xiong, Yueming Wu, Mi Tian, Jianying Yao, Sisi Huang, Lidi Zhang, Yizhu Chen, Sheng Zhang, Zhenliang Wen, Hangxiang Du, TaoWang, Yongan Liu, Wenzhe Li, Yan Xu, Jean-louis Teboul, Dechang Chen
Publikováno v:
Annals of Intensive Care, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract Background The mortality of extensively drug-resistant Gram-negative (XDR GN) bacilli-induced ventilator-associated pneumonia (VAP) is extremely high. The purpose of this study was to compare the efficacy and safety of inhaled (IH) plus intr
Externí odkaz:
https://doaj.org/article/1e460ee17bc24261a31a53f18675fa41
Publikováno v:
Annals of Intensive Care, Vol 10, Iss 1, Pp 1-8 (2020)
Abstract Background Currently, there are no reliable predictors of risk of development and severity of acute kidney injury (AKI) in septic patients. The surfactant protein D (SP-D) polymorphism rs721917C/T is associated with a greater susceptibility
Externí odkaz:
https://doaj.org/article/88fc9903154846168c1971e4fbff8840
Autor:
Justin R. Ortiz, Laurie Kamimoto, Ronald E. Aubert, Jianying Yao, David K. Shay, Joseph S. Bresee, Robert S. Epstein
Publikováno v:
Emerging Infectious Diseases, Vol 14, Iss 8, Pp 1280-1283 (2008)
We reviewed information from a US pharmacy benefits manager database from 2004 through 2005 during periods with little influenza activity. We calculated rates of oseltamivir prescriptions to enrollees. Prescription rates increased significantly from
Externí odkaz:
https://doaj.org/article/6fb04e3379284c0593526d5e7832a18c
Autor:
Chaoan Lai, Jianying Yao
Publikováno v:
Lecture Notes in Electrical Engineering ISBN: 9789811659621
Lecture Notes in Electrical Engineering
Lecture Notes in Electrical Engineering
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7502a10adcfdba1edd75cf8c5904d7d1
https://doi.org/10.1007/978-981-16-5963-8_112
https://doi.org/10.1007/978-981-16-5963-8_112
Publikováno v:
Annals of Intensive Care
Annals of Intensive Care, Vol 10, Iss 1, Pp 1-8 (2020)
Annals of Intensive Care, Vol 10, Iss 1, Pp 1-8 (2020)
Background Currently, there are no reliable predictors of risk of development and severity of acute kidney injury (AKI) in septic patients. The surfactant protein D (SP-D) polymorphism rs721917C/T is associated with a greater susceptibility to AKI in
Autor:
Sheldon Kong, Jamie Partridge, Jianying Yao, Sreevalsa Appukkuttan, Stephen J. Freedland, Jacqueline Parkin, Yuxian Du
Publikováno v:
Journal of Clinical Oncology. 39:e18675-e18675
e18675 Background: Novel AA agents, such aspalutamide (Apa), enzalutamide (Enza) and darolutamide (Daro) are approved for the treatment of nmCRPC. In clinical trials, they were associated with AEs such as fatigue, fractures and falls. This study aime
Publikováno v:
Health Affairs. 31:1836-1846
Improving adherence to medication offers the possibility of both reducing costs and improving care for patients with chronic illness. We examined a national sample of diabetes patients from 2005 to 2008 and found that improved adherence to diabetes m
Autor:
Felix W. Frueh, Jeffrey A. Breall, Ronald E. Aubert, Rolf P. Kreutz, Robert S. Epstein, Eric J. Stanek, David A. Flockhart, Jianying Yao, J. Russell Teagarden, Zeruesenay Desta, Todd C. Skaar
Publikováno v:
Pharmacotherapy. 30:787-796
Study Objective. To investigate the potential impact of proton pump inhibitors (PPIs) on the effectiveness of clopidogrel in preventing recurrent ischemic events after percutaneous coronary intervention (PCI) with stent placement. Design. Population-
Autor:
Laurie Kamimoto, Jianying Yao, Robert S. Epstein, Joseph S. Bresee, David K. Shay, Ronald E. Aubert, Justin R. Ortiz
Publikováno v:
Emerging Infectious Diseases
We reviewed information from a US pharmacy benefits manager database from 2004 through 2005 during periods with little influenza activity. We calculated rates of oseltamivir prescriptions to enrollees. Prescription rates increased significantly from
Publikováno v:
Journal of Clinical Oncology. 35:215-215
215 Background: To describe treatment patterns and costs of care associated with the use of FDA-approved agents for metastatic castrate-resistant prostate cancer (mCRPC). Methods: Two large integrated claims databases (MarketScan, PharMetrics) were u